Latest updates for Dpnt.ns
Fresh curated links around DPNT.NS are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Diploma PLC (DPMAY) Q2 2026 Earnings Call Transcript
- Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
- Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
धितोपत्र बोर्डको प्रतिबद्धता : नेप्से पुनर्संरचना, एनआरएन र पेन्सन कोषको सहभागिता
२५ जेठ काठमाडौं । पूँजी बजार नियामक नेपाल धितोपत्र बोर्ड ३४ औं वर्षमा प्रवेश गरेको छ । वार्षिकोत्सवका अवसरमा प्रतिबद्धता पत्र सार्वजनिक गर्दै अध्यक्ष उत्तरकुमार खत्रीले पूँजी बजारल...
This analyst just raised his price target on D2L
National Bank Financial analyst Doug Taylor says D2L’s (D2L Stock Quote, Chart, News, Analysts, Financials TSX:DTOL) first-quarter results showed improving ARR trends and “compelli...
Free shares! NSE IPO DRHP reveals curious case of 5,000 shares landing in wrong demat account
According to the DRHP, NSE and Nuvama Wealth Finance filed a civil suit before the Delhi High Court against Kashmiri Lal Rana and NSDL in May 2025, alleging that 5,000 NSE shares w...
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.